Lynne Bui
Direttore/Membro del Consiglio presso THARIMMUNE, INC.
Patrimonio netto: - $ in data 30/04/2024
Posizioni attive di Lynne Bui
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| THARIMMUNE, INC. | Direttore/Membro del Consiglio | 01/07/2021 | - |
| Independent Dir/Board Member | 01/07/2021 | - | |
Khloris Biosciences, Inc.
 Khloris Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Khloris Biosciences, Inc. operates as biotechnology company. The firm offers drug discovery, vaccine and cell therapies for treatment and prevention of cancer. The company was founded by Lynne A. Bui and Joseph C. Wu in June 2017 and is headquartered in Mountain View, CA. | Amministratore Delegato | 01/06/2017 | - |
| Fondatore | - | - | |
| Presidente | 01/06/2017 | - | |
| Global Cancer Research Institute | Presidente | - | - |
| Fondatore | - | - | |
| GCRI Foundation, Inc. | Presidente | - | - |
| Fondatore | - | - |
Storia della carriera di Lynne Bui
Precedenti posizioni note di Lynne Bui
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Direttore Tecnico/Scientifico/R&S | - | - |
Intellikine LLC
 Intellikine LLC Pharmaceuticals: MajorHealth Technology Intellikine LLC develops and manufactures small molecule drugs for the treatment of cancer. The company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders. Intellikine was founded on May 2nd, 2007 and is headquartered in La Jolla, CA. | Direttore Tecnico/Scientifico/R&S | - | - |
| EXELIXIS, INC. | Direttore Tecnico/Scientifico/R&S | - | - |
Formazione di Lynne Bui
| University of California, Berkeley | Undergraduate Degree |
| David Geffen School of Medicine | Graduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 9 |
| 2 |
Posizioni
| Chief Tech/Sci/R&D Officer | 3 |
| Founder | 3 |
| Chairman | 2 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| EXELIXIS, INC. | Health Technology |
| Aziende private | 6 |
|---|---|
Khloris Biosciences, Inc.
Khloris Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Khloris Biosciences, Inc. operates as biotechnology company. The firm offers drug discovery, vaccine and cell therapies for treatment and prevention of cancer. The company was founded by Lynne A. Bui and Joseph C. Wu in June 2017 and is headquartered in Mountain View, CA. | Commercial Services |
| Tharimmune, Inc. | |
| Global Cancer Research Institute | |
| GCRI Foundation, Inc. | |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Intellikine LLC
Intellikine LLC Pharmaceuticals: MajorHealth Technology Intellikine LLC develops and manufactures small molecule drugs for the treatment of cancer. The company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders. Intellikine was founded on May 2nd, 2007 and is headquartered in La Jolla, CA. | Health Technology |
- Borsa valori
- Insiders
- Lynne Bui
- Esperienza